GlobeNewswire BiotechnologyDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 04:01:00·⟳ 抓取 04:02:02·⚡ 决策 10-21 04:03:29 +1m27s·6.6 天前
Lakefront Biotherapeutics 公告完成既有回购计划上周买入10.78万股，属例行执行披露无新增催化
这是受监管要求的回购执行周报/完成确认：回购框架4个月前已公开，本周买入行为发生在10月12-16日（早已成交），公告仅事后披露成交价量并宣告计划完成，没有新的回购授权、上调规模、业绩或管线增量；约285万欧元的单周回购对一家纳斯达克上市生物科技公司相对市值不具实质弹性，属典型程序性披露。
📄 原文GlobeNewswire Biotechnology↗ 原文
Acquisition of Own Shares
Mechelen, Belgium; October 20, 2026, 22.01 CEST; regulated information Within the framework of the repurchase program a…
不做 Lakefront Biotherapeutics NV（LKFT.US）
既有回购计划的事后执行与完成披露，买入已于10月12-16日成交且计划6月9日已公开，无新增未预期信息，单周约285万欧元规模相对市值无实质弹性，属程序性公告无交易 edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Lakefront 公告的是既有回购计划的例行执行结果与完成确认，买入发生在数日前且计划早已披露，无新增未预期事实或资金流冲击，不具备事件交易 edge。
🔎 新鲜度:最早出现 2026-10-20 · 扩散 low · price-in 风险 high ↗
主要风险
- 公司同时在Euronext上市，欧元成交价与纳斯达克美元股价存在跨市场口径差异，但不改变本次无增量信息的结论
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-20 · 影响 none
公告仅宣告旧计划完成，未提及新增回购规模、管线进展或业绩上调，无支持做多的增量利好
检索:Lakefront LKFT buyback expansion new authorization pipeline news October 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未改变结论；事件本身无增量，故无需用先例校准幅度
方向:无可对照先例；但既有回购计划的例行执行/完成披露在各市场普遍被视为无新增信息的程序性公告
涨幅量级:不足以据以设定止盈幅度，未进入交易
形态:无
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 9 ms
{"result": "search_processed_events:agent query=`lakefront 107804 shares repurchased €2.85 million | lakefront biotherapeutics repurchase own shares october 2026 | lkft share buyback program completed june 9 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选
原文全文
展开原文 · 5,168 字
Mechelen, Belgium; October 20, 2026, 22.01 CEST; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between October 12, 2026, and October 16, 2026, it has repurchased 107,804 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:
Date of purchase
Market/MTF
Number of shares
Average price paid (€)
Total (€)
Lowest price paid (€)
Highest price paid (€)
10/12/2026
XAMS
20,818
26.51
551,843.54
26.38
26.68
10/12/2026
CEUX
4,350
26.56
115,543.40
26.44
26.68
10/12/2026
AQEU
429
26.55
11,391.15
26.44
26.58
10/12/2026
TQEX
186
26.53
4,935.12
26.44
26.62
10/13/2026
XAMS
20,811
26.36
548,480.15
26.16
26.52
10/13/2026
CEUX
2,446
26.41
64,590.05
26.30
26.50
10/13/2026
AQEU
1,896
26.41
50,081.13
26.30
26.52
10/13/2026
TQEX
634
26.37
16,717.06
26.30
26.46
10/15/2026
XAMS
23,113
26.49
612,304.97
26.04
26.98
10/15/2026
CEUX
3,219
26.26
84,545.75
26.14
26.92
10/15/2026
AQEU
1,520
26.22
39,859.26
26.16
26.88
10/15/2026
TQEX
333
26.13
8,701.02
26.12
26.30
10/16/2026
XAMS
24,946
26.57
662,730.40
26.18
26.76
10/16/2026
CEUX
2,287
26.63
60,909.67
26.28
26.78
10/16/2026
AQEU
65
26.46
1,719.90
26.46
26.46
10/16/2026
TQEX
751
26.65
20,013.10
26.40
26.80
Total
107,804
26.48
2,854,365.69
26.04
26.98
As of market close on October 16, 2026, Lakefront holds 1,985,157 of its own ordinary shares.
With these purchases, the repurchase program announced on June 9, 2026, has been fully completed.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit
https://www.lakefrontbio.com
or follow us on
LinkedIn
or
X
.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com
Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.
Attachment
20261016 LakefrontEN RNS Announcement
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between October 12, 2026, and October 16, 2026, it has repurchased 107,804 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:
Date of purchase
Market/MTF
Number of shares
Average price paid (€)
Total (€)
Lowest price paid (€)
Highest price paid (€)
10/12/2026
XAMS
20,818
26.51
551,843.54
26.38
26.68
10/12/2026
CEUX
4,350
26.56
115,543.40
26.44
26.68
10/12/2026
AQEU
429
26.55
11,391.15
26.44
26.58
10/12/2026
TQEX
186
26.53
4,935.12
26.44
26.62
10/13/2026
XAMS
20,811
26.36
548,480.15
26.16
26.52
10/13/2026
CEUX
2,446
26.41
64,590.05
26.30
26.50
10/13/2026
AQEU
1,896
26.41
50,081.13
26.30
26.52
10/13/2026
TQEX
634
26.37
16,717.06
26.30
26.46
10/15/2026
XAMS
23,113
26.49
612,304.97
26.04
26.98
10/15/2026
CEUX
3,219
26.26
84,545.75
26.14
26.92
10/15/2026
AQEU
1,520
26.22
39,859.26
26.16
26.88
10/15/2026
TQEX
333
26.13
8,701.02
26.12
26.30
10/16/2026
XAMS
24,946
26.57
662,730.40
26.18
26.76
10/16/2026
CEUX
2,287
26.63
60,909.67
26.28
26.78
10/16/2026
AQEU
65
26.46
1,719.90
26.46
26.46
10/16/2026
TQEX
751
26.65
20,013.10
26.40
26.80
Total
107,804
26.48
2,854,365.69
26.04
26.98
As of market close on October 16, 2026, Lakefront holds 1,985,157 of its own ordinary shares.
With these purchases, the repurchase program announced on June 9, 2026, has been fully completed.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit
https://www.lakefrontbio.com
or follow us on
or
X
.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com
Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.
Attachment
20261016 LakefrontEN RNS Announcement
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
644a23cf54· 2026-10-21 04:03 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前